<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> has markedly increased in the last few decades and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is regarded as the precursor lesion of this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the study was to quantify the <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> risk associated with <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drug</z:chebi> use and to determine at which stage chemoprevention with this drug is the most effective in <z:mp ids='MP_0003278'>esophageal inflammation</z:mp> - <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> - <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence </plain></SENT>
<SENT sid="2" pm="."><plain>A literature search was performed to identify studies published between 1998 and 2009 for relevant risk estimates </plain></SENT>
<SENT sid="3" pm="."><plain>Fixed and random effect meta-analytical techniques were conducted for aspirin, nonaspirin <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi>, and <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Four cohort and 10 case-control studies were included </plain></SENT>
<SENT sid="5" pm="."><plain>Use of aspirin and nonaspirin <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> in <z:mpath ids='MPATH_458'>normal</z:mpath> population was associated with a reduced risk of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (odds ratio [OR]: 0.73, 95% confidence interval [CI]: 0.65-0.83; OR: 0.84, 95% CI: 0.72-0.98, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>The use of <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> was associated with a reduced risk of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (relative risk [RR]: 0.64, 95% CI: 0.42-0.96) in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> patients </plain></SENT>
<SENT sid="7" pm="."><plain>However, no obvious dose-effect relationships were found </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, we discovered a reverse association between drugs use and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> risk in people without a history of upper <z:e sem="disease" ids="C0017178" disease_type="Disease or Syndrome" abbrv="">gastrointestinal tract disorders</z:e> (OR: 0.57, 95% CI: 0.43-0.77, P= 0.12) </plain></SENT>
<SENT sid="9" pm="."><plain>Our meta-analyses suggest a protective effect of <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> on the risk of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Our results also suggest that the drugs might act after the formation of Barrett's epithelium in the <z:mp ids='MP_0003278'>esophageal inflammation</z:mp> - <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> - <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence </plain></SENT>
</text></document>